

Real World Evidence in Europe: The Results of an Expert Survey

Gill JL¹, Albanell J², Avouac B³, Dank M⁴, Duncombe R⁵, Fink-Wagner A-H⁶, Hutton J⁷, Jahnz-Rozyk K⁸, Kössler I⁹, Podrazilova K¹⁰, Schramm W¹¹, Spandonaro F¹², Vaz Carneiro A¹³, Wartenberg M¹⁴ and Kanavos PG¹

Background

- Use of **Real World Evidence (RWE)** – derived from analysis or synthesis of **real world data (RWD)** obtained from sources such as patient registries, electronic health records and claims databases – is increasingly recognised as a valuable source of information for market-access and reimbursement decision making
- Aim:** To develop and conduct a **global survey** in order to better understand the **use of RWE** in these contexts

Method


- Survey tool developed iteratively with key stakeholders in academia, health services, government bodies and patient organisations from ten European countries
- The survey, made available in English via Qualtrics from March 2017, contained **35 qualitative and quantitative, closed- and open-ended questions** on the use of RWE for licensing and coverage recommendations, RWE ownership and the future of RWE.
- Survey link was distributed to a number of global contacts for completion

Results


Respondent Demographics

Respondent Country:

- 40 respondents between March and August 2017




Respondent Role:




Country RWE Utilisation

Does your country accept a lower level of evidence for any therapeutic class/product type?




Please rate the *current* value of RWE for decision making in your country

NB bigger bar = higher value




Respondent Opinion

In what situations can RWE support improved decision making?




In your opinion, will RWE ever play a similar role to RCT data in drug evaluations?



The future of RWE

What are the *barriers* to enhanced RWE use?



Barriers to enhanced RWE use:


- Data validity
- Registry quality
- Data quality
- Data quantity

Steps for overcoming barriers:

- Develop definition and guideline for RWE
- Guarantee data quality
- Control bias and confounding factors
- Advance data management
- Introduce incentives for clinicians to record data

Rate the potential value of RWE, and its use in decision-making, in your country over the *next 3 years*

NB – bigger bar = higher value



- RWE predicted to play a more minimal role in Bosnia, Germany, Austria and Belgium over the next 3 years
- More important role in Cyprus, Russia, Bulgaria
- Will have a more important role in economic evaluations and reassessment/re-review
- Slightly less important role in regulatory based decision-making

Conclusions

- 40 respondents from 22 countries
- Most countries accepted lower levels of evidence for **orphan/oncology**
- RWE thought to have more value currently in **clinical and reimbursement** based decision-making, rather than regulatory
- Most respondents see RWE as a **complement to RCT**, rather than replacement
- Most of the opinion that RWE will become more **valuable over time**
- In order for increased RWE value both **data availability and quality** need to **improve**
- RWE thought to play role in **economic evaluations and reassessment/re-review** in next 3 years

Acknowledgments

The authors would like to thank all experts who participated in this survey. We would also like to thank Olina Efthymiadou for assistance with survey development. This survey was sponsored via an unrestricted educational grant from F. Hoffman-La Roche AG.